Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...

Novartis (NVS)’ Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the agency’s website. Published first on TheFly ...

Novartis is expanding its prospects in cardiometabolic ... is currently in Phase 3 testing in patients with atrial fibrillation who have a high risk for stroke or systemic embolism.

Novartis has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, its chief executive said.

Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...

Novartis NOVN0.30%increase; green up pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal ...

Although these guidelines don’t directly affect rankings, they provide useful insights into what Google views as high-quality content. This update reflects Google’s evolving approach to ...

As for why, exactly, Novartis chose this year and this effort to make its first foray into the high-profile (and high-cost) realm of Super Bowl advertisements, Bulto said the reasons were twofold.

Are you a print subscriber? Activate your account. By Tim Nudd - 19 hours 17 min ago By Amir Farhang - 19 hours 17 min ago By Ashley Joseph - 1 day 17 hours ago By Ad Age Staff - 1 day 17 hours ...